CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Swisscom nine-month revenue falls, raises 2026 operating free cash flow outlook 

By Reuters News


Overview

  • Switzerland telecom group's nine-month revenue fell 2.1% yr/yr to CHF 10.94 bln

  • Net income for the period rose 2.4% to CHF 1.01 bln

  • Operating free cash flow climbed 14.5% on an adjusted basis


Outlook

  • Swisscom confirms 2026 revenue guidance at CHF 14.7-14.9 bln

  • Company expects 2026 EBITDAaL of CHF 5.0-5.1 bln

  • Swisscom raises 2026 operating free cash flow outlook to above CHF 2.0 bln


Result Drivers

  • COST EFFICIENCY - Co said higher profitability in Switzerland was driven by cost-efficiency measures and increased IT business contribution

  • SYNERGIES IN ITALY - Italian segment's profitability improved mainly due to cost synergies

  • VALUE STRATEGY ITALY - Co said its value strategy in Italy helped stabilise key indicators, including moderating revenue decline and stable mobile ARPU


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

CHF 10.94 bln

9M Net Income

CHF 1.01 bln

9M Capex

CHF 2.04 bln


Analyst Coverage

  • The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 8 "hold" and 10 "sell" or "strong sell"

  • The average consensus recommendation for the integrated telecommunications services peer group is "buy."

  • Wall Street's median 12-month price target for Swisscom AG is CHF605.00, about 14.9% below its November 4 closing price of CHF711.00

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • Nov 5 - Switzerland's Swiss Re 9M net income rises on lower catastrophe losses

  • Nov 4 - Swiss pharma industry behind in technology and clinical trials, index shows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.